Quinazoline Derivatives as VEGF Inhibitors

The invention relates to quinazoline derivatives of formula (I), wherein in is an integer from 1 to 3; R1 represents halogeno or C1-3alkyl; X1 represents -O-; R2 is selected from one of the following three groups: 1) C1-5akylR3 (wherein R3 is piperidin-4-yl which may bear one or two substituents sel...

Full description

Saved in:
Bibliographic Details
Main Authors Thomas, Andrew Peter, Hennequin, Laurent Francois Andre, Stokes, Elaine Sophie Elizabeth
Format Patent
LanguageEnglish
Published 09.09.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to quinazoline derivatives of formula (I), wherein in is an integer from 1 to 3; R1 represents halogeno or C1-3alkyl; X1 represents -O-; R2 is selected from one of the following three groups: 1) C1-5akylR3 (wherein R3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy; 2) C2-5alkynylR3 (wherein R3 is as defined hereinbefore); 3) C2-5alkynylR3 (wherein R3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
Bibliography:Application Number: US202117150856